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A recent report provides new insights into the mech-
anisms of neurodegeneration. In a mouse mutant with
progressive cerebellar and retinal degeneration, the
expression of the apoptotic protein AIF was found to
be downregulated leading paradoxically to apoptosis
of neurons that is associated with an imbalance in
free radical metabolism and cell cycle re-entry.
The study of neurodegenerative diseases, such as
Alzheimer’s disease and Parkinson’s disease, is an
exciting area of current biological research. Novel
insights into the mechanisms that underlie neurode-
generation are coming from a number of approaches
including, as shown in a recent article in Nature,
studies of mice with inherited spontaneous mutations
[1]. By characterizing the genetic and biochemical
abnormalities in a mouse neurodegenerative mutant
termed harlequin, Susan Ackerman and colleagues
link oxidative stress in the adult brain with cell cycle
reactivation and apoptosis of postmitotic neurons.
And in the process, the Ackerman group has helped
uncover a novel function for the mitochondrial protein
apoptosis-inducing factor (AIF).
The Harlequin Mouse: Ataxia with low AIF
The harlequin mouse was first described as an X-
linked mutant mouse with little hair [2]. But it was the
phenotype of progressive ataxia that caught the atten-
tion of investigators at the Jackson Laboratory who
described the cerebellar pathology that correlates with
this phenotype [3]. In the recent work [1], the molecu-
lar genetic abnormality responsible for the harlequin
mouse was mapped by positional cloning. The expres-
sion of one candidate gene, encoding apoptosis-
inducing factor (AIF), was found to be reduced by 80%
in the harlequin mouse due to an insertion of a mouse
leukemia virus in the AIF locus. As AIF had been previ-
ously described to be pro-apoptotic, the genetic find-
ings left the authors with the paradoxical question of
how a reduction in the level of a pro-apoptotic protein
triggers neuronal cell death and degeneration.
AIF as an Apoptosis Inducer
AIF was first identified by Guido Kroemer’s group as a
mitochondrial protein that induces apoptosis in a
caspase-independent manner [4]. Stimuli that lead to
apoptosis were found to promote the translocation of
AIF from the mitochondria to the cytosol and nucleus
[4]. Once in the nucleus, AIF imparts a powerful apop-
totic signal that leads to chromatin condensation and
DNA fragmentation. The crystal structure of AIF
revealed a surface with positive electrostatic potential
that may mediate AIF’s ability to bind to DNA in a
sequence-independent manner leading to large-scale
DNA cleavage [5]. That AIF is an important mediator of
apoptosis was confirmed in genetic studies: AIF-defi-
cient embryonic stem cells are resistant to serum depri-
vation-induced apoptosis and the first wave of
apoptosis during embryogenesis is defective in the AIF-
deficient mouse embryos [6].
How apoptotic signals trigger AIF release remains
to be elucidated at this point. Apoptotic stimuli,
including free radicals, that induce DNA damage and
activate poly ADP-ribose polymerase (PARP) in the
nucleus have recently been suggested to trigger the
release of AIF from mitochondria as a secondary con-
sequence of consumption of the metabolite nicoti-
namide adenine dinucleotide (NAD+) [7]. However,
how the alteration in NAD metabolism is involved in
the translocation of AIF from the mitochondria to the
nucleus remains unclear.
AIF as an Oxidoreductase
While AIF’s role as an apoptotic protein is beginning
to be characterized, the Nature study has elevated the
status of another function of AIF that has so far
received little attention. Presumably, a reduction in the
apoptosis-inducing function of AIF does not explain
the progressive neuronal degeneration in the harlequin
mouse. A clue as to how a hypomorphic allele of AIF
might trigger neurodegeneration comes from molecu-
lar, structural and biochemical studies of AIF. The
molecular characterization of AIF suggested that AIF
contains a domain related in sequence to bacterial
oxidoreductases [4]. Crystallographic studies of AIF
revealed the presence of an oxidoreductase domain
that resembles the ferrodoxin reductase component of
bacterial biphenyl dioxygenases [8]. In biochemical
studies, the oxidoreductase domain of AIF was
demonstrated to harbor NAD(P)H oxidase activity in
vitro [9]. Interestingly, the apoptotic and NAD(P)H
oxidase activities of AIF were found to operate inde-
pendently of each other [9]. These data suggest that
AIF is a bifunctional protein whose oxidoreductase
activity might participate in the function of AIF in mito-
chondria. However, the precise physiological role of
AIF in mitochondria remains to be elucidated.
In examining potential mechanisms that underlie the
progressive cerebellar neurodegeneration in the harle-
quin mouse, the Ackerman group followed the hypoth-
esis that the low expression of AIF leads to the
impairment of free radical homeostasis and consequent
oxidative stress in neurons. Based on the comparison
of AIF to hydrogen peroxide scavenging bacterial oxi-
doreductases, the authors proposed that low AIF leads
to the accumulation of hydrogen peroxide. Consistent
with Ackerman’s hypothesis, the harlequin mouse con-
tains increased lipid peroxidation and compensatory
Dispatch
Current Biology, Vol. 13, R19–R21, January 8, 2003, ©2003 Elsevier Science Ltd. All rights reserved. PII S0960-9822(03)01382-9
Department of Pathology, Harvard Medical School, 200
Longwood Avenue, Boston, Massachusetts 02115, USA. 
E-mail: azad_bonni@hms.harvard.edu
increases in the activity of catalase and glutathione
reductase [1]. However, several questions remain in the
interpretation of the reported data on free radical home-
ostasis in the harlequin mice. The physiological sub-
strates of AIF’s oxidoreductase activity in the
mitochondria and thus the reactive oxygen species that
are increased in AIF-deficient neurons are currently
unknown [9]. Although AIF has NAD(P)H oxidase activ-
ity in vitro that generates superoxide anion radicals,
NAD(P)H may not be the true substrate of AIF in vivo [9].
The lowering of such an activity in AIF-deficient cells
would be expected to reduce rather than raise the free
radical load in the cell [10]. Importantly, AIF has been
suggested not to have hydrogen peroxide scavenging
activity in vitro presenting a contradiction to the
hypothesis proposed in the Nature study [9].
Supporting Ackerman’s hypothesis that abnormali-
ties in free radical pathways contribute to the degen-
eration of AIF-deficient neurons is the evidence of
increased and selective sensitivity of cultured harle-
quin cerebellar granule neurons to hydrogen peroxide-
induced apoptosis, a phenotype that is rescued by the
expression of AIF [1]. To help establish the link
between loss of AIF’s oxidoreductase activity and
neurodegeneration, it will be important to test the
effect of mutating the oxidoreductase domain of AIF
on AIF’s ability to rescue granule neurons from hydro-
gen peroxide-induced apoptosis.
Harlequin Mouse Neurons Re-enter the Cell Cycle
One of the most interesting aspects of the study on the
harlequin mouse is that the cell cycle machinery is
reactivated in the degenerating postmitotic neurons as
shown by the incorporation of bromodeoxyuridine and
the expression of DNA replication proteins in these
neurons [1]. Based on these data, the Ackerman group
proposed the model whereby oxidative stress in the
harlequin mouse instructs susceptible neurons to
resume the cell cycle only to succumb to apoptosis.
The hypothesis that abortive cell cycle re-entry
might be a fundamental mechanism by which postmi-
totic neurons undergo apoptosis was formulated
some time ago in studies of developmentally regu-
lated neuronal apoptosis (reviewed in [11]). The with-
drawal of neurotrophic factors or neuronal activity
from the extracellular environment of postmitotic
neurons in the developing brain triggers the activation
of G1/S components of the cell cycle in neurons
including the phosphorylation of the retinoblastoma
protein and the consequent activation of the tran-
scription factor E2F. In addition to the activation of
G1/S cell cycle components, recent results indicate
that G2/M cell cycle proteins are also activated in
dying neurons. The mitotic kinase Cdc2 mediates
apoptosis of activity-deprived cerebellar granule
neurons by directly phosphorylating and activating a
component of the cell death machinery [12].
Accumulating evidence also suggests that neurons
in the adult brain re-enter the cell cycle upon exposure
to pathogenic stimuli that induce neuronal degenera-
tion. In patients afflicted with Alzheimer’s disease and
other neurodegenerative diseases of the brain, evi-
dence of reactivation of the mitotic machinery is sug-
gested by the presence of immunoreactivity of Cdc2
and its activator cyclin B1 in degenerating forebrain
neurons [13–15]. Interestingly, evidence of DNA 
synthesis and replication per se has been sparse 
in human neurodegenerations but may occur in
Alzheimer’s disease [16]. Although evidence of cell
cycle re-entry appears often in neurodegenerative dis-
eases, the mechanisms by which pathogenic stimuli
trigger cell cycle re-entry are not yet clear. In addition
and more importantly, the role of cell cycle reactiva-
tion in triggering neuronal cell death and degeneration
in these disorders remains unknown.
In the harlequin mouse, AIF-deficient cerebellar
granule neurons appear to undergo DNA synthesis and
replication in large numbers [1]. It will be interesting to
determine if the robust DNA replication observed in
AIF-deficient mouse cerebellar granule neurons is a
process that occurs generally in neurodegenerative
diseases. The Ackerman group correlates the response
of neurons to oxidative stress and the reactivation of
the cell cycle. However, the molecular links between
oxidative stress and cell cycle re-entry in neurons have
yet to be characterized. In addition, it remains to be
determined whether cell cycle re-entry constitutes the
mechanism by which AIF deficiency triggers neuronal
degeneration and apoptosis in the harlequin mouse.
Perspectives
The Nature study raises the possibility that the investi-
gation of mouse mutants might be valuable to the
study of degenerative diseases of the human brain in a
similar manner as spontaneous mouse mutants have
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Figure 1. Model of how AIF deficiency might lead to neuronal
degeneration.
Low expression of AIF leads to the generation of reactive
oxygen species (ROS) that induce postmitotic neurons to enter
the cell cycle. A signal that emanates from ROS directly, from
the reactivated cell cycle machinery, or from DNA damage
during DNA replication leads to the release of cytochrome c
and the activation of caspase-dependent apoptosis.
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been to our understanding of brain development. The
study suggests that AIF deficiency leads to an imbal-
ance in free radical homeostasis that induces the sus-
ceptible cerebellar granule and retinal neurons to enter
the cell cycle and undergo apoptosis (Figure 1). Like all
breakthroughs, the harlequin study raises many inter-
esting questions. As we know so little about the normal
oxidoreductase function of AIF, the precise nature of
the imbalance in free radical metabolism in harlequin
neurons needs to be identified. How the abnormally
regulated free radicals in AIF-deficient neurons induce
cell cycle re-entry would also be important to address.
Finally, several questions remain that are of general
significance to the neurodegeneration field. Do the
mechanisms of neurodegeneration in the harlequin
mouse operate in human neurodegenerative diseases?
Why does AIF deficiency lead to the specific degener-
ation of cerebellar granule and retinal neurons? Why
does the AIF-deficiency phenotype only begin to
appear in the mature brain and why is it progressive in
nature? Investigation of these types of question should
improve our understanding of degenerative diseases of
the human brain.
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